What is the key information in the instructions for Tirzepatide?

Tirzepatide (Tirzepatide) is a drug produced by Eli Lilly (Eli The innovative anti-diabetic drug developed by Lilly Company was first approved by the FDA in 2022 for the treatment of type 2 diabetes, and its trade name is Mounjaro. As a dual agonist (GLP-1 and GIP receptor agonist), tilsiparatide has significant hypoglycemic and weight loss effects and has attracted widespread attention in the current field of diabetes and metabolic syndrome treatment. The following content will comprehensively analyze the key information of tisiparatide in terms of indications, usage and dosage, pharmacological effects, adverse reactions, contraindications and precautions based on the instructions.

1. Indications and clinical uses

According to the instructions, tisiparatide is mainly suitable for adults with type 2 diabetes to improve blood sugar control and can be used as an auxiliary treatment drug when diet control and exercise are insufficient. In addition, more and more studies and real-world data show that tilsiparatide has significant weight loss effects in overweight or obese patients, so it is also being explored for obesity treatment (it has been approved for weight loss in some countries).

It should be noted that tisiparatide is not suitable for patients with type 1 diabetes, nor can it be used as a first-aid drug for diabetic ketoacidosis.

2. Usage and dosage

Tisiparatide is a subcutaneous injection that is used once a week. The starting dose is usually 2.5 mg once a week. After four weeks of injection, the dose can be gradually increased according to the patient's tolerance. The usual maintenance dose is 5 mg, 10 mg or 15 mg once a week.

The injection method is subcutaneous injection, and the abdomen, thigh or upper arm can be selected as the injection site. The injection site should be changed with each injection to reduce the risk of skin irritation.

The medication time does not need to be linked to meal times, but it is recommended to inject at the same time every week to maintain a stable drug effect. If an injection is missed for any reason, the injection should be made up within 96 hours before the next injection. If this time has passed, skip the injection and do not increase dose compensation.

3. Pharmacological mechanism of action

Tisiparatide is a GIP/GLP-1 dual receptor agonist, which is its biggest feature that distinguishes it from traditional GLP-1 drugs (such as semaglutide). GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) are both members of the incretin family. They jointly regulate multiple metabolic links such as insulin secretion, appetite and body weight.

Specific mechanisms of action include:

1. Enhance insulin secretion: Promote insulin release and lower blood sugar under high blood sugar conditions;

2. Inhibit glucagon secretion: reduce liver glucose output;

3.Delay gastric emptying: delay the rise in blood sugar after a meal;

4. Suppresses appetite and promotes weight loss: acts on the central nervous system and reduces food intake;

5.Improve pancreatic isletβ cell function: Helps delay the progression of diabetes.

6.It is precisely because of this dual-target mechanism that tilsiparatide can significantly reduce body weight while lowering blood sugar. It is known as "one of the strongestGLP-1 drugs."

4. Adverse reactions

According to the instructions and clinical research data, the adverse reactions of tilsiparatide are similar to otherGLP-1 drugs, but due to its dual mechanism of action, some reactions may be more obvious. Common adverse reactions include:

1.Gastrointestinal reactions: such as nausea, vomiting, diarrhea, constipation, abdominal pain, etc.;

2. Decreased appetite: helpful for weight loss, but some patients may have insufficient nutritional intake due to this;

3.Risk of hypoglycemia: low when used alone, but if combined with insulin or sulfonylureas, the risk of hypoglycemia will increase;

4.Injection site reactions: such as erythema, induration or itching;

5.Risk of pancreatitis: Although it is a rare adverse reaction, the instructions emphasize the need to be alert to the occurrence of acute pancreatitis.

In addition, long-term safety studies are ongoing, particularly on the potential effects on medullary thyroid cancer, gallbladder disease, and changes in kidney function.

5. Taboos and Precautions

The instructions state that tilsiparatide is contraindicated in the following situations:

1.Those who are known to be allergic to tisiparatide or its excipients;

2.Those with a family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome2 type (MEN2);

3.1Patients with type 2 diabetes and diabetic ketoacidosis.

In terms of precautions, the patient's past medical history should be assessed before using tilsiparatide, especially whether there is pancreatitis, gastrointestinal disease, abnormal liver and kidney function, or thyroid disease. At the same time, weight changes, blood sugar control, and potential adverse reactions should be closely monitored during treatment, and patients should be informed that they should seek medical treatment in time if they experience persistent abdominal pain or sudden weight loss.

For patients receiving multiple antidiabetic drugs concurrently, the doses of other drugs may need to be adjusted to reduce the occurrence of hypoglycemia.

Tisiparatide, as an innovative drug for the treatment of type 2 diabetes, has excellent weight control capabilities in addition to its hypoglycemic effect, providing a new treatment option for the majority of patients with diabetes and obesity. The key information in the instructions covers its indications, usage and dosage, pharmacological mechanisms, adverse reactions, contraindications, etc. A comprehensive understanding of these contents will help doctors carry out individualized treatment scientifically and rationally. At the same time, with the deepening of research, tilsiparatide may also become a new standard for weight loss treatment, with broad application prospects in the future.

Reference materials:https://www.drugs.com/tirzepatide.html